| Dr Joseph F Emrich, MD | |
|
1000 E Mountain Dr, Mc 37-31, Wilkes Barre, PA 18711-0027 | |
| (518) 421-7109 | |
| Not Available |
| Full Name | Dr Joseph F Emrich |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 43 Years |
| Location | 1000 E Mountain Dr, Wilkes Barre, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649262858 | NPI | - | NPPES |
| 01175295 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 181020-1 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Berkshire Medical Center | Pittsfield, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Berkshire Faculty Services Inc | 8224068424 | 222 |
News Archive
Healthcare professionals using new time-saving strategies to coordinate care for patients having a heart attack saw dramatic improvement in "door-to-balloon" (D2B) times-the time from when a patient enters the hospital to the time blood flow is restored to the heart by opening a blockage with angioplasty. The faster patients are treated, the more likely they are to survive. The results are published by Yale researchers and their colleagues in the December 15 issue of the Journal of the American College of Cardiology.
The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, a structural change that increases the risk for future heart problems, according to new research in Circulation: Cardiovascular Imaging, an American Heart Association journal.
Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.
› Verified 1 days ago
| Entity Name | Berkshire Faculty Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548212939 PECOS PAC ID: 8224068424 Enrollment ID: O20050817001122 |
News Archive
Healthcare professionals using new time-saving strategies to coordinate care for patients having a heart attack saw dramatic improvement in "door-to-balloon" (D2B) times-the time from when a patient enters the hospital to the time blood flow is restored to the heart by opening a blockage with angioplasty. The faster patients are treated, the more likely they are to survive. The results are published by Yale researchers and their colleagues in the December 15 issue of the Journal of the American College of Cardiology.
The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, a structural change that increases the risk for future heart problems, according to new research in Circulation: Cardiovascular Imaging, an American Heart Association journal.
Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph F Emrich, MD 23 Relyea Rd, Voorheesville, NY 12186-9714 Ph: (518) 421-7109 | Dr Joseph F Emrich, MD 1000 E Mountain Dr, Mc 37-31, Wilkes Barre, PA 18711-0027 Ph: (518) 421-7109 |
News Archive
Healthcare professionals using new time-saving strategies to coordinate care for patients having a heart attack saw dramatic improvement in "door-to-balloon" (D2B) times-the time from when a patient enters the hospital to the time blood flow is restored to the heart by opening a blockage with angioplasty. The faster patients are treated, the more likely they are to survive. The results are published by Yale researchers and their colleagues in the December 15 issue of the Journal of the American College of Cardiology.
The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, a structural change that increases the risk for future heart problems, according to new research in Circulation: Cardiovascular Imaging, an American Heart Association journal.
Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.
› Verified 1 days ago
Dr. Victor Chukwuemeka Udekwu, M.D Neurological Surgery Medicare: May Accept Medicare Assignments Practice Location: 545 N River St Ste 240, Wilkes Barre, PA 18702 Phone: 570-706-2620 Fax: 570-706-2627 | |
Jeffrey Daniel Oliver, Neurological Surgery Medicare: Medicare Enrolled Practice Location: 1000 E Mountain Dr, Wilkes Barre, PA 18711 Phone: 570-808-3290 Fax: 570-808-3298 | |
Dr. John H. Presper, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1000 E Mountain Blvd, Wilkes Barre, PA 18711 Phone: 570-819-5370 Fax: 570-819-5371 | |
Kenneth C Liu, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 E Mountain Blvd, Wilkes Barre, PA 18711 Phone: 570-808-6026 Fax: 570-808-3298 | |
Dr. Michel Lacroix, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 E Mountain Blvd, Wilkes Barre, PA 18711 Phone: 570-820-6026 Fax: 570-826-7943 | |
Dr. Zaid Sameer Aljuboori, M.D., Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 E Mountain Dr, Wilkes Barre, PA 18711 Phone: 570-808-3290 Fax: 570-808-3298 | |
Itay Melamed, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 E Mountain Blvd, Wilkes Barre, PA 18711 Phone: 570-808-6026 Fax: 570-808-3298 |